Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs Fluticasone/Salmeterol in COPD
NCT01860066Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Area under the curve (AUC) 0-12 hours for FEV1 at 12 weeks. Planned start Dec 2013; status: withdrawn.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01860066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860066.